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Abstract
Background: Pancreatic ductal adenocarcinoma (PDA) remains the most aggressive cancers with a 5-year survival
below 10%. Systemic delivery of chemotherapy drugs has severe side effects in patients with PDA and does not
significantly improve overall survival rate. It is highly desirable to advance the therapeutic efficacy of chemotherapeutic
drugs by targeting their delivery and increasing accumulation at the tumor site. MUC1 is a membrane-tethered
glycoprotein that is aberrantly overexpressed in > 80% of PDA thus making it an attractive antigenic target.
Methods: Poly lactic-co-glycolic acid nanoparticles (PLGA NPs) conjugated to a tumor specific MUC1 antibody, TAB004,
was used as a nanocarrier for targeted delivery into human PDA cell lines in vitro and in PDA tumors in vivo. The PLGA
NPs were loaded with fluorescent imaging agents, fluorescein diacetate (FDA) and Nile Red (NR) or isocyanine green (ICG)
for in vitro and in vivo imaging respectively or with a chemotherapeutic drug, paclitaxel (PTX) for in vitro cytotoxicity assays.
Confocal microscopy was used to visualize internalization of the nanocarrier in vitro in PDA cells with high and
low MUC1 expression. The in vivo imaging system (IVIS) was used to visualize in vivo tumor targeting of the
nanocarrier. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay was used to determine in
vitro cell survival of cells treated with PTX-loaded nanocarrier. One-sided t-test comparing treatment groups at
each concentration and two-way ANOVAs comparing internalization of antibody and PLGA nanoparticles.
Results: In vitro, TAB004-conjugated ICG-nanocarriers were significantly better at internalizing in PDA cells than
its non-conjugated counterpart. Similarly, TAB004-conjugated PTX-nanocarriers were significantly more cytotoxic
in vitro against PDA cells than its non-conjugated counterpart. In vivo, TAB004-conjugated ICG-nanocarriers
showed increased accumulation in the PDA tumor compared to the non-conjugated nanocarrier while sparing
normal organs.
Conclusions: The study provides promising data for future development of a novel MUC1-targeted nanocarrier
for direct delivery of imaging agents or drugs into the tumor microenvironment.
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Background
Pancreatic Cancer is a highly aggressive disease with a
5-year relative survival rate of ~ 9% [1]. Greater than
90% of all pancreatic cancers arise in the epithelial
ducts of the pancreas and are designated pancreatic
ductal adenocarcinomas (PDA). Only 18-20% of patients
diagnosed with PDA are eligible for surgical resection
followed by chemo and radiation therapies. For majority of
PDA patients, chemo and radiation therapies are the only
choices. However, due to chemo-resistance, the overall
survival rate with or without surgical resection remains
dismal [2]. It is established that one of the reasons for
failed therapy is the inefficient delivery of chemotherapy
drugs to the tumor site, likely due to the dense stroma
and deficient vascular network in the pancreatic tissue
microenvironment [3, 4]. Therefore, there is a pressing
need to develop a novel drug delivery system for PDA
that can increase the drug accumulation and uptake in
a tumor specific manner [5].
Nanoparticles (NPs) modified to degrade in the tumor
microenvironment or target tumor antigens are promising
platforms for the targeted delivery of therapeutic drugs to
specific cells and tissues [6–9]. NPs formulated from
biodegradable and biocompatible polymers, such as
Poly lactic-co-glycolic acid (PLGA), are being utilized
increasingly in research due to their excellent systemic
characteristics [10]. PLGA NPs allow for the encapsulation
of a variety of hydrophobic chemotherapeutics or imaging
agents, and can thereby facilitate the systemic delivery of
these otherwise insoluble compounds with localization at
the tumor site. This localization is the result of the
enhanced permeability and retention effect (EPR), which
is caused by the vasculature permeability in tumors being
greater than in normal tissues, and thus provide a mech-
anism of selection for the NPs, as they do not penetrate
into neighboring normal tissue [11, 12]. The unorganized
structure of the tumor and lack of lymphatic drainage
prolong the retention of NPs after they escape from the
leaky vasculature [13]. PLGA NPs with polyethylene
glycol (PEG) displayed at the surface have been shown
to increase circulatory half-lives of the NPs, while surface
modification with targeting agents have been shown to aid
in localization of the NPs selectively at targeted tissues
[14–17]. Novel chemotherapeutic agents and combinations
like FOLFIRINOX (5-fluorouracil, oxaliplatin, irinotecan,
and leucovorin) or Abraxane (nab-paclitaxel, an albumin-
coated formulation of paclitaxel) have been developed and
have seen some success [18, 19]. The combination of
gemcitabine and nab-paclitaxel has been shown to increase
the intratumor concentration of gemcitabine by roughly
three-fold in xenograft models [20, 21]. Paclitaxel, a taxane
agent, (PTX) is one of the most widely used anticancer
drugs approved for the treatment of many types of cancer.
PTX interferes with cell division by interacting with
the polymer form of tubulin and promoting microtu-
bulin assembly. This stabilizes the polymers against
depolymerization, which induces M-phase cell cycle
arrest and cell death [22, 23]. Targeted NPs consisting of
PLGA encapsulated PTX will provide a drug delivery
system that would increase delivery of PTX to the tumor
site, due to the EPR effect [24]. Systemic administration of
the drug loaded NPs, however, have many problems
associated with it. For instance, if the NP is too large,
issues can arise that prevent them from reaching the
tumor site, as the NPs have to cross through several
biological barriers, such as blood vessels, tissues, organs,
and cells. Without any specificity for the tumor site, it
may be necessary to use fairly high doses of NPs and drugs
to achieve sufficient local concentrations. In PDA, due to
poor vascularization and despoplasia, non-targeted NPs
may not suitable. Conjugating the NPs with tumor
targeting moieties could possibly overcome some of
these challenges.
Mucin-1 (MUC1), is a transmembrane protein with an
extracellular domain that is heavily glycosylated [25]. It
is normally expressed on epithelial cells of the mammary
gland, esophagus, stomach, duodenum, uterus, prostate,
lung, and pancreas [26]. In healthy tissues, the negatively
charged glycosylated extracellular domain of MUC1 creates
a physical barrier and an anti-adhesive surface, preventing
pathogenic colonization [27]. In over 80% of PDA, MUC1
is hypoglycosylated and overexpressed [28] which in turn is
also associated with higher metastasis and poor prognosis
[29, 30]. These characteristics ranked MUC1 as one of the
best tumor antigens for targeted therapy [31]. We have
developed a novel monoclonal antibody, TAB004
(OncoTAb, Inc., Charlotte, NC), which specifically targets
the hypoglycosylated form MUC1 (tMUC1) [32–34].
This study was aimed at investigating the targeting
ability of TAB004 conjugated PLGA NPs in vitro and in
vivo. NR, FDA, and ICG were used as the imaging
agents and PTX as the chemotherapeutic drug. We
hypothesized that the conjugation of TAB004 to the
surface of PLGA NPs will increase their accumulation
and duration at the tumor site and thereby increase the
overall therapeutic index of the treatment. For this
purpose, PTX, ICG, or FDA&NR were encapsulated in
PEGylated PLGA NPs and then conjugated to TAB004.
Unconjugated particles were used as controls. Internaliza-
tion, retention, and therapeutic efficacy were evaluated




All chemical reagents used for the study were of analytical
grade. Poly(DL-lactide-co-glycolide) MW 20,000 (PLGA)
(50:50) PolySciences, Inc. (Warrington, PA). Polyethylene
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glycol Mw 1000 (PEG1000), Poly(vinyl alcohol) MW 6000
(PVA) (80 mol% hydrolyzed), 1,1′-carbonyldiimidazole
(CDI), 1,3-diaminopropane (DAP), Dextrose were purchased
from Sigma Aldrich (St. Louis, MO). Paclitaxel was
purchased from Matrix Scientific (Columbia, SC), ICG
was purchased from Chem-Impex (Wood Dale, IL).
TAB004 monoclonal antibody was obtained from OncoTAb,
Inc. (Charlotte, NC, USA).
Cell culture
Human PDA cell lines including BxPC3, HPAC, HPAFII,
and MIA PaCa-2 were purchased from ATCC (Manassas,
VA). Murine PDA cell line, KCM was generated in our
lab [35]. KCM, HPAC, HPAF II, and MIA PaCa-2 were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM, 11965-092, Gibco). BxPC3 cell lines were
maintained in RPMI medium 1640 (RPMI, 11875-093,
Gibco). Growth media for these cell lines were supple-
mented with 10% fetal bovine serum (FBS, Gibco), 3.
4 mM ˪-glutamine, 90 units (U) per ml penicillin, and
90 μg/ml streptomycin (Cellgro).
Determination of NP loading
For the paclitaxel NP (PTX) formulation a 20 mg sample
of was dissolved into 600 μl of DMSO-d6 and the con-
centration of the respective cargo determined using 1H
NMR at 25 °C by comparing unique resonances of the
cargo to the methylene residue of PLGA at [5.2 ppm].
For the fluorescein diacetate (FDA), indocyanine green
(ICG), and Nile red (NR) NP formulations, a sample of
nanomaterial (2-4 mg) was dissolved into DMSO and
the amount of cargo quantified by UV-Vis.
Encapsulation Efficiency ¼ Amount of cargo encapsulated
Amount of cargo used
 100
Determination of NP size and polydispersity
Particle size, polydispersity index (PDI), along with zeta
potential were determined by dynamic light scattering
(Zetasizer Nano, Malvern Instruments) Table 1.
Cargo release profiles
Release profiles of NPs were modeled using FDA NPs.
The release characteristics of these particles were char-
acterized in phosphate buffered saline (PBS) at pH 7.4.
Synthesis of PCL14K-PEG1000
PCL14K-PEG1000 was prepared according to the following
procedure. Polycaprolactone (2 g, Mw ~ 14,000) was
added to a 50 ml oven dried round-bottom flask fitted
with a claisen adapter and equipped with a magnetic
stir bar, a rubber septum, and a reflux condenser with
attached drying tube. To this was added 20 ml of thionyl
chloride via syringe, and the rubber septum replaced with
a ground-glass stopper, and the resulting solution heated
to reflux for 3 h. The thionyl chloride was then removed
under reduced pressure using a rotary evaporator. The
resulting residue was placed under a nitrogen atmosphere
and 50 ml of freshly distilled tetrahydrofuran (THF) was
added by cannula followed by PEG1000-diol (2.9 g, 20
equivalent) and triethylamine (2 ml, 14.35 mmol). The
resulting solution was left to stir for 18 h at room
temperature. This solution was then poured into 500 ml
of DI water under vigorous stirring to precipitate the
desired product and remove unreacted PEG1000 diol. The
precipitate was isolated by filtration, re-dissolved into THF
(50 ml), and precipitated as before. This process was
repeated three times. Finally, the isolated product was dried
under vacuum at 25 °C for 72 h. The desired product was
isolated as a solid white material (1.13 g, 53%). 1H NMR
(500 MHz CDCl3): δ 1.36 (m, -CH2CH2CH2-), 1.63 (m,
-CH2CH2CH2-), 2.28 (t, -C(O)CH2-), 3.62 (s, -OCH2CH2-),
4.04 (t, -OCH2).
Synthesis of PCL14K -PEG1000-NH2
PCL14K -PEG1000-NH2 was prepared by the according to
the following procedure. PCL14K -PEG1000 (1 g) was added
to a 50 ml oven dried 2-neck round-bottom flask
equipped with a magnet stir bar and a rubber septum with
nitrogen inlet. To this was added 20 ml of dry methylene
chloride (DCM) followed by 1,1′-carbonyldiimidazole
(100 mg, .62 mmol) and the resulting solution left to stir
for 6 h at room temperature. To this was added 1,3-diami-
nopropane (1 ml, 12.19 mmol) and the resulting solution
left to stir for 12 h at room temperature. The DCM was
then removed under reduced pressure using a rotary evap-
orator. The resulting viscous yellow liquid was dissolved
into THF (20 ml) and precipitated by pouring the solution
into 250 ml of vigorously stirred DI water. The precipitate
was isolated by filtration, re-dissolved into THF (20 ml),
and precipitated as before. This process was repeated
three times. Finally, the isolated product was dried under
vacuum at 25 °C for 72 h. The desired product was
isolated as a yellow solid (.5 g, 50%). Although the reso-
nances for the end-group -C(O)NHCH2CH2CH2NH2- are
Table 1 Structural Properties of PTX, FDA, NR, and ICG
Nanomaterials
Nanomaterial HD (nm) PDI ZP (ζ)
PTX NPs 141.8 ± .6 .155 ± .009 −7.6 ± .2
FDA NPs 171.3 ± 1.2 .129 ± .004 −6.4 ± .2
NR NPs 209.3 ± .6 .175 ± .007 −6.7 ± .1
ICG NPs 180.7 ± .9 .076 ± .006 −6.8 ± .1
HD Hydrodynamic Diameter, PDI Polydispersity Index, ZP Zeta Potential
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not assigned due to obfuscation of these resonances by the
polymer backbone, the polymer tested positive for the pres-
ence of primary amines using the Kaiser test [36]. H NMR
(500 MHz CDCl3): δ 1.37 (m, -CH2CH2CH2-), 1.64 (m,
-CH2CH2CH2-), 2.29 (t, -C(O)CH2-), 3.63 (s, -OCH2CH2-),
4.05 (t, -OCH2).
Nanoparticle preparation: General method
Nanoparticles (NPs) were prepared by the nanoprecipi-
tation according to the method of Langer et al. [37].
Briefly; 100 mg of PLGA (50:50, Mw ~ 20 K), 5 mg of
PCL-PEG1000, 1 mg PCL-PEG1000-NH2, and 1 - 5 mg of
cargo was dissolved into 10 ml of acetone. This solution
was then added dropwise via syringe into a stirred solution
of 1% PVA (20 ml) at a rate of 90 ml/hr. controlled using a
syringe pump. The resulting colloidal suspension was then
transferred to a 100 ml round-bottom flask, and the
acetone removed under reduced pressure using a rotary
evaporator. NPs were then purified by centrifugation
(25 min, 30,000×g) using three successive washes of
sterile filtered 18 Ω water at 4 °C. The resulting NP pellet
was then resuspended into sterile filtered 18 Ω water
(10 ml), whereupon dextrose (10 mg) was added as a
lyoprotectant. This colloidal suspension was then flash
frozen in liquid nitrogen then lyophilized at 25 °C and
50 mTorr for 24 - 48 h resulting in a flocculent solid.
Paclitaxel (PTX), Fluorescein Diacetate (FDA), and Nile Red
(NR) were all prepared according to the general method
described above. See Table 2 for the amount of cargo
used in the preparation of the respective nanomaterials.
ICG preparation
ICG NP’s were prepared similarly using a modified nano-
precipitation method according to procedure reported by
Cai [38]. Briefly; 100 mg of PLGA (50:50, Mw ~ 20 K),
5 mg of PCL-PEG1000, 1 mg PCL-PEG1000-NH2 was
dissolved into 9 ml of acetonitrile. Meanwhile 1 mg of
ICG was dissolved into 1 ml of sterile filtered 18 Ω water.
The two solutions were then mixed, and vortexed rapidly
for 2 min. The resulting solution was then added dropwise
via syringe into a stirred solution of 1% PVA (20 ml) at a
rate of 90 ml/hr. controlled using a syringe pump. The
resulting colloidal suspension was then transferred to a
100 ml round-bottom flask, and the acetonitrile removed
under reduced pressure using a rotary evaporator. NPs
were then purified by centrifugation (25 min, 30,000×g)
using three successive washes of sterile filtered 18 Ω water
at 4 °C. The resulting NP pellet was then resuspended into
sterile filtered 18 Ω water (10 ml), whereupon dextrose
(10 mg) was added as a lyoprotectant. This colloidal
suspension was then flash frozen in liquid nitrogen, and
lyophilized at 25 °C and 50 mTorr for 24 - 48 h resulting
in a flocculent green solid.
FDA release profiles
1 ml Solutions of FDA NPs (1 mg/ml) in PBS (pH 7.4)
were incubated with constant stirring at 37 °C over 72 h.
100 μl samples were taken at the indicated time-points
and centrifuged (16,000 x g) to pellet out the remaining
NPs. 50 μl of NP free buffer was removed carefully so as
not to disturb the pellet, and 20 μl of 5% NaOH added
to hydrolyze the liberated FDA. Absorbance measure-
ments were recorded at 490 nm. These values were
compared to a control sample having been dissolved in a
50:50 acetonitrile (CAN):H2O solution to liberate the
entire sample of FDA from the NPs, and hydrolyzed as
above.
SEM imaging
Lyophilized nanoparticles were re-suspended in H2O at
0.01 mg/mL concentrations and sonicated for 10 s.
Samples were placed on SPI 5 × 5 silicon chips and
dried overnight at 40 °C. Scanning electron microscopy
(SEM) images were obtained with a Raith 150 microscope
operated at 10 kV.
Generation of BxPC3.MUC1, BxPC3.Neo, and KCM-Luc
Full-length MUC1 gene was cloned into the pLNCX.1
vector consisting of the neomycin resistance gene for
retroviral infection. GP2-293 cells were transfected with
MUC1 pLNCX.1 and pVSV-G vectors and the resulting
viral supernatant used to infect a MUC1-null human
PDA cell line, BxPC3. These cells were designated
BxPC3.MUC1 cells. BxPC3.MUC1 serves as MUC1-high
positive control. BxPC3.Neo represent BxPC3 cells that
express the empty vector and therefore serves as the
MUC1-negative controls [30]. KCM cell line was generated
from spontaneous PDA tumors arising in the PDA.MUC1
triple transgenic mice. This cell line is syngeneic to the
C57/Bl6 mouse background and expresses human MUC1
[34, 35]. Retroviral transduction of KCM cells with MSCV
Luciferase PGK-Hygro (MSCV Luciferase PGK-hygro was
a gift from Scott Lowe, Addgene plasmid # 18782) was
performed by transfecting GP2-293 cells with the MSCV
Luciferase PGK-Hygro and pVSV-G vectors and using the
subsequent viral supernatant to infect KCM cells.
Table 2 Cargo Loading of PTX, FDA, NR, and ICG into
Nanomaterials
Nanomaterial Cargo Loading (mg) Amount Encapsulated
(mg/100 mg NPs)
EE (%)
PTX NPsa 5 2.3 ± .1 46.7 ± 1.8
FDA NPsb 5 1.7 ± .1 34.2 ± .9
NR NPsb 2 .26 ± .01 13.1 ± .6
ICG NPsb 1.75 .39 ± .01 22.1 ± .3
EE Encapsulation Efficiency. aDetermined by 1H NMR. bDetermined by UV-Vis
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Conjugation of TAB004 to PLGA NPs
TAB004 conjugation to PLGA nanoparticles was performed
using NuLink conjugation kit (NuChemie). PLGA nanopar-
ticles were weighed out into an appropriate Eppendorf tube.
To a vial containing 1 mg of the NuLink© bis-electrophile
thioester was added 1 drop of DMSO to assist with dissol-
ution, then 500 μl of 18 Ω H2O was added. The solution
was vortexed until all of the labeling reagent was dissolved.
The PLGA nanoparticles were re-suspended in 200 μl of
18 Ω H2O. The labeling solution was added dropwise to the
nanoparticles while under a gentle vortex and allowed to
incubate at room temperature (how long time) after mixing.
The labeled nanoparticles were centrifuged at 21,000 rcf and
4 °C to pellet them. The supernatant was removed and the
labeled nanoparticles re-suspended in 200 μl of 18 Ω H2O.
30 μg of TAB004 at mg/ml conc (in azide free buffer) was
then added to the labeled NP solution in one portion. The
next day, the nanoparticles were centrifuged at 21,000 rcf
and 4 °C to pellet them and the supernatant discarded.
Nanoparticles were re-suspended into desired working
volume of PBS. Successful TAB004 conjugation to the
PLGA nanoparticle was confirmed using FACS (BD
Fortessa) and an anti-mouse IgG1-FITC secondary
antibody.
Cell viability assays
Cell viability assays were performed using MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide)
(Fisher Scientific, USA). Optimal number of cells per cell
line were plated into 96-well tissue culture plates to
ensure cells would not be over confluent after 48 h post
treatment. 24 h after cells were plated, they were treated
with corresponding concentrations of dimethyl sulfoxide
(DMSO), PTX, blank PLGA nanoparticles, PTX loaded
PLGA nanoparticles, and TAB004 conjugated PTX loaded
PLGA nanoparticles for 1.5 h. After 1.5 h the treatments
were washed off with 1× PBS and 200 μl of fresh media
was added to the wells and cell lines were incubated for
48 h at 37 °C, > 90% humidity, and 5% CO2 conditions.
Following the 48 h incubation, the media was replaced
with 100 μl of phenol red free media and 10 μl of MTT
was added to each well. Plates were incubated at 37 °C, >
90% humidity, and 5% CO2 conditions for 4 h, after which
the media and MTT were removed, 100 μl of DMSO
added, and incubated at 37 °C for 10 min. The plates were
then read using a ThermoFisher Scientific MultiScan GO.
Cell viability data for each treatment group (PTX, NP
loaded with PTX, and TAB004 conjugated to NPs loaded
with PTX) was normalized to their own vehicle control
cell viabilities (DMSO and Blank NPs).
Internalization of NPs
Cell lines were plated into 4-chamber well slides (154,
917, LAB-TEK) at optimal concentration to ensure cells
would not be over confluent after 24 h. 24 h after cells
were plated, they were treated with fluorescein (20 μg/ml),
or fluorescein diacetate and Nile Red containing PLGA
nanoparticles at 1 mg/ml concentration for 1.5 h at 37 °C,
> 90% humidity, and 5% CO2 conditions. After treatment,
cells were washed with PBS for 5 min (3×) and fixed with
4% formaldehyde. Prolong Gold Antifade reagent with
DAPI (P36935, Molecular Probes) was applied to mount
coverslips. Images were acquired on an Olympus Fluoview
FV 1000 confocal microscope.
Specificity and internalization of TAB004
TAB004 conjugation to pHrodo Red was performed using
the pHrodo Red, succinimidyl ester (pHrodo Red, SE) kit
(P36600, Molecular Probes). TAB004 conjugation to indo-
cyanine green (ICG) was performed using the ICG Label-
ing Kit –NH2 (LK31-10, Dojindo Molecular Technologies,
Inc.). All conjugations were performed using manufacturer
protocols. Cell lines were plated into 4-chamber well slides
(154,917, LAB-TEK) at optimal concentration to ensure
cells would not be over confluent after 24 h. 24 h after cells
were plated, they were treated with 5 μl of TAB004-
phRodo Red conjugation solution for various time points
at 37 °C, > 90% humidity, and 5% CO2 conditions. During
the last 5 min of treatment, Wheat Germ Agglutinin-Alexa
Fluor 488 conjugate (W11261, Molecular Probes), was
added to each chamber at 5 μg/ml. The cells were washed
with PBS for 5 min (3×) and fixed with 4% formaldehyde.
Prolong Gold Antifade reagent with DAPI (P36935,
Molecular Probes) was applied to mount coverslips.
Images were acquired on a GE Healthcare Life Sciences
DeltaVision Elite Imaging microscope.
Mouse strains
C57Bl/6 mice were purchased from Jackson Laboratory
and housed at UNC Charlotte’s vivarium.
Orthotopic tumor model
C57/Bl6 female mice were injected in the pancreas with
5 × 105 KCM-Luc cells and allowed to recuperate for
7 days before any experiments were performed. This
study and all procedures were performed after approval
from the Institutional Animal Care and Use Committee
of UNC Charlotte.
Visualization of KCM-Luc orthotopic tumors, TAB004-ICG,
and TAB004 conjugated PLGA NPs with ICG
Orthotopic KCM-Luc tumor bearing C57/Bl6 mice were
injected with 125 μl of Redijet D-Luciferin (760,504, Perkin
Elmer) intraperitoneally and imaged 25 min later with a
Perkin Elmer IVIS Spectrum. Orthotopic KCM-Luc tumor
bearing C57/Bl6 mice were injected with 25 μg of
TAB004-ICG, 50 mg/kg of NP w/ICG, or 50 mg/kg of
TAB004-NP w/ICG intraperitoneally and imaged at
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various time points with a Perkin Elmer IVIS Spectrum.
Mice were euthanized at the end of imaging studies.
All procedures were conducted in accordance to the
Institutional Animal Care and Use Committee of UNC
Charlotte. All mice and organ images and region of
interests (ROIs) were acquired and processed in Living
Imagine 4.3.1 (Caliper Life Sciences, Waltham, MA).
Results
Nanoparticle preparation and characterization
We evaluated the size and release profile of PLGA NPs
to determine an optimal size for use (Fig. 1a). As shown,
PCL14K-PEG1K and PCL14K-PEG1K-NH2 partitions into
the aqueous environment during self-assembly of the
nanoparticles, thereby generating a nanoparticle having a
pegylated surface with a small percentage of nucleophilic
amines available for chemical modification. During self-
assembly the cargo is encapsulated in the hydrophobic
core. The functionalization of the NP surface was
performed using the NuLink bis-electrophile (Fig. 1b).
Fluorescein Diacetate (FDA) PLGA NPs were used as
a model system to investigate the size and release profile
of the NP platform described (Fig. 2a, b). In vitro cargo
release of the NPs was evaluated in PBS at pH 7.4. FDA
was steadily released over the course of 120 h. The percent
of FDA released at 24, 48, 72, and 96 h was 24%, 37%, 50%,
59%, and 70% respectively (Fig. 2b).
PLGA NPs internalize into BxPC3.MUC1 and BxPC3.Neo
human PDA cell lines
We determined whether the PLGA NPs internalizes into a
human PDA cell line. Wild-type BxPC3 cells have minimal
expression of endogenous MUC1. We generated BxPC3.
MUC1 cells that stably express full-length MUC1. As
control, we generated BxPC3.Neo that expresses the
empty vector. BxPC3.MUC1 cells express high levels of
MUC1 while BxPC3.Neo cells express minimal levels of
MUC1 [30]. In the later experiments, this will enable us
to assess the specificity of the TAB004 antibody in an
otherwise genetically identical PDA cell line. BxPC3.
MUC1 and BxPC3.Neo cell lines were treated for 1.5 h
with FDA and Nile Red loaded NPs. This matched the
total treatment time of PDA cell lines in the cell viability
assay. After 1.5 h, FDA and NR loaded PLGA NPs inter-
nalized through endocytosis into both BxPC3.MUC1 and
BxPC3.Neo cell lines equally (Fig. 3) suggesting that
internalization is independent of MUC1 expression
levels. Punctate green fluorescence, from the hydrolysis
of FDA in the NPs, can be seen within the cytoplasm of
the cells, indicating internalization of the NPs (Fig. 3).
Fluorescence is only observed if FDA is hydrolyzed
within the cells [39]. Although we detect a slight trend
of increased endocytosis in the BxPC3.MUC1 versus
BxPC3.Neo cells, the difference is not statistically
significant.
TAB004 antibody internalizes into PDA cell lines that
express tMUC1
Next we determined the specificity of TAB004 to MUC1
and quantified the internalization of TAB004 antibody by
fluorescent microscopy (Fig. 4). The presence and uptake
of TAB004 was visualized by conjugating the antibody to
pHrodo Red, which is non-fluorescent outside the cell,
but fluoresces red only post endocytosis (Fig. 4a). The
green fluorescence is wheat germ agglutinin that stains
the cell membrane. The fluorescent signal from TAB004
is significantly increased in BxPC3.MUC1 when compared
Fig. 1 Nanoparticle preparation and surface functionalization. a Nanoparticle preparation by nanoprecipitation; (b) Functionalization of the NP
surface using the NuLink bis-electrophile
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to BxPC3.Neo cells at all time points (Fig. 4b). There is
some internalization observed in BxPC3 Neo, which can
be caused by the very low level of endogenous MUC1 that
is present, or by non-specific endocytosis as PDA cells
have been shown to actively swallow their surroundings
through macropinocytosis [40, 41].
TAB004 conjugated PTX loaded PLGA NPs are specific for
and inhibit growth of tMUC1 expressing cells
The successful conjugation of TAB004 to the surface of
the NPs (T-NPs) was determined by flow cytometry
(Additional file 1: Figure S1). The linking reagent, a
thioester, was tested and was successful in linking
TAB004 to the NPs (Additional file 1: Figure S1B). Flow
cytometry data shows a shift in fluorescence when NPs
are conjugated to TAB004 and labeled with FITC conju-
gated anti-mouse IgG1. Unconjugated NPs did not dis-
play any shift in fluorescence (Additional file 1: Figure
S1A). NPs without the linking reagent but incubated with
TAB004, or FITC anti-mouse IgG1, or both also served as
controls and as expected did not show any shift in fluores-
cence signal. This suggests that the thioester linker was
successful in conjugating TAB004 to the NPs.
We compared the internalization of unconjugated
NPs to TAB004 conjugated NPs (T-NPs) in MUC1 high
BxPC3.MUC1 versus MUC1 low BxPC3.Neo cells.
Fig. 2 Characterization of PLGA NPs: Fluorescein Diacetate (FDA) PLGA NPs were used as a model system to investigate the size and release
profile of the NP platform described (a, b). In vitro cargo release of the NPs was evaluated in PBS at pH 7.4. FDA was steadily released over the
course of 120 h. The percent of FDA released at 24, 48, 72, and 96 h was 24%, 37%, 50%, 59%, and 70% respectively (b)
Fig. 3 Internalization of PLGA NPs in: (A) BxPC3 MUC1; (B) BxPC3 Neo. Results shown are representative images (n = 3)
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BxPC3.MUC1 and BxPC3.Neo cells were treated with
FDA loaded NPs or T-NPs and fluorescence signal
quantified over time (Fig. 5). There was no significant
increase in fluorescence between T-NPs and NPs in the
MUC1-low BxPC3.Neo cells (Fig. 5c). However, a signifi-
cant increase in fluorescence was detected in BxPC3.
MUC1 cells treated with T-NPs compared to when treated
with NPs. This significant increase in fluorescence was
observed at 60 and 90 min post treatment. The data in-
dicates that linking TAB004 to the NPs was highly
effective in longer term retention of the NPs within the
MUC1-high cells compared to NPs alone and that this
retention was antigen specific.
Therefore, we next determined the cytotoxicity of PTX
loaded T-NPs compared to PTX loaded NPs in the same
cells (BxPC3.Neo and BxPC3.MUC1) as well as in a
panel of other human PDA cell lines with varying levels
of MUC1 expression and sensitivity to PTX (Fig. 6). The
comparison we were interested in was between the
treatment groups (NP and T-NPs) and not necessarily
between the various cell lines. We selected a single
dose of PTX for each cell line where at least 90% of
cells remained viable post PTX treatment (~IC10). We
determined if there was any added cytotoxic effect of
NPs or T-NPs loaded with PTX at the same concentration
as the PTX alone. There was no difference in viability
between PTX, NP-PTX or T-NP-PTX treated BxPC3.
Neo cells (Fig. 6). This was expected based on Fig. 5c
where no difference in internalization and retention
was observed in BxPC3.Neo cells between NPs and
T-NPs. On the other hand, in MUC1-expressing BxPC3
MUC1, MiaPaca2, and HPAC cells, we observed a
significant decrease in cell viability between NP-PTX
versus T-NP-PTX at a single dose (Fig. 6). This
decrease was not noted in HPAF-II cell even though
these cells express high levels of MUC1 (Fig. 6). The reasons
for the lack of responsiveness to T-NPs in HPAF-II cells are
not currently known. Although the effect of T-NPs versus
NPs is modest, it is highly significant because of PDA’s high
resistance to chemotherapy.
Fig. 4 Specificity and internalization of TAB004 in BxPC3 MUC1 and Neo: (a) representative images cells treated with TAB004 conjugated to
pHRodo red (n = 3); (b) quantification of images determine by the number of cells associated with TAB004 divided by total number of cells. Data
shown is mean ± SEM (n = 3) and determine by two-way ANOVA and Bonferroni’s post-hoc test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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TAB004 accumulates at the tumor site and its
conjugation to PLGA NPs appears to increase their
accumulation in an Orthotopic PDA tumor model
We demonstrated the specificity of TAB004 in vitro, but the
same needed to be determined in vivo. C57BL/6 immune
competent mice bearing murine syngeneic orthotopic KCM
tumors [35] were injected intraperitoneally with TAB004
conjugated with ICG and imaged 24 h post injection. The
KCM cells stably expressed the luciferase gene and thus bio-
luminescent tumors could be visualized by IVIS post
luciferin injection. TAB004 localizes and persists specif-
ically at the tumor site 24 h later (Fig. 7a-d). Images of
4 representative mice are shown. It is clear that the
TAB004-ICG localizes only to the bioluminescent pancre-
atic tumors. The fluorescent radiant efficiency values for
region of interests (ROIs) around the tumor site were
acquired for TAB004-ICG injected mice and displayed
significant increase over tumor bearing control mice
that were not injected with TAB004-ICG (Fig. 7e).
Next, we tested ICG loaded NPs and ICG loaded T-NPs
in mice bearing the same KCM bioluminescent orthotopic
tumors to determine if TAB004 can increase the accumula-
tion of NPs at the tumor site (Additional file 2: Figure S2).
ICG loaded NPs appear to clear from the mouse between
Fig. 5 Internalization of TAB004 conjugated NPs loaded with fluorescein diacetate (FDA): (a) representative images of BxPC3 MUC 1 (n = 3) treated with T-
NPs; (b) representative images of BxPC3 Neo (n = 3) treated with T-NPs; (c) and (d) quantification of fluorescence using Image J to determine corrected total
cell fluorescence (CTCF). Data shown is mean± SEM (n = 3) and determined by a one-sided t-test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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24 and 48 h post injection (Additional file 2: Figure S2),
similar to the biodistribution profile of ICG loaded NPs
injected in non-tumor bearing mice (data not shown).
However, ICG loaded T-NPs appeared to accumulate
and persist at the tumor site 24 and 48 h post injection
(Additional file 2: Figure S2B). Ex vivo images of the
tumor and liver of the mice were taken 48 h post injection
and ICG loaded T-NPs seem to accumulate and persist in
the tumor while ICG load NPs cannot be detected in the
tumor post 48 h. We noted that the fluorescence in the
liver was identical for ICG loaded T-NPs and ICG loaded
NPs (Additional file 2: Figure S2C) suggesting that the
tumor localization is extremely high for T-NPs versus
NPs. Thus, TAB004 conjugated NPs may be developed as
a potential platform for targeted delivery of not only PTX,
but other drugs and imaging agents directly to the
Fig. 6 Cell viability of PDA cell lines treated with PTX, PTX loaded NPs and PTX loaded TAB004 conjugated NPs. Concentration of PTX is 3.05 × 10− 3 μg/ml.
Data shown is mean ± SEM (n = 3) and determine by a one-sided t-test comparing treatment groups at each concentration, *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.000
Fig. 7 In vivo imaging of TAB004-ICG in orthotopically injected bioluminescent tumor bearing mice (ICG - red/yellow, tumor (luciferase-expressing) –
rainbow, n = 4): (a) mouse 1; (b) mouse 2; (c) mouse 3 and 4 ventral view; (d) mouse 3 and 4 side view; (e) quantification of fluorescent radiant
efficiency values in TAB004-ICG injected and control mice, *p < 0.05
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pancreatic tumor while reducing toxicity to other major
organs. Future studies will evaluate the in vivo anti-tumor
efficacy in several models of PDA.
Discussion
The ability to target drug-loaded nanoparticles to the
tumor site would greatly enhance efficacy of the drug
and reduce toxicity. PLGA is one of the most effective
biodegradable polymers used to construct polymeric
nanoparticles (NPs). It has been approved by the US
FDA for use in drug delivery systems due to controlled
and sustained- release properties, low toxicity, and biocom-
patibility with tissue and cells [42–44]. PEG-functionalized
PLGA NPs are especially desirable, as pegylated-NP
platforms have demonstrated significantly reduced systemic
clearance compared with similar particles without PEG.
This design parameter is important for the passive target-
ing of nanocarrier to tumor by the EPR effects [45]. To
enhance tumor-specific targeting, in this study, we aimed
to investigate PEG-functionalized PLGA NPs conjugated
to monoclonal antibody TAB004. TAB004 specifically
recognizes the hypoglycosylated tumor form of MUC1
[32, 46, 47] while sparing recognition of MUC1 on normal
epithelial cells. Over 80% of PDA expresses this tumor
form of MUC1 and is an established target for immuno-
therapy [48, 49]. In Fig. 4, we show that TAB004 specif-
ically internalizes in the BxPC3.MUC1 ells but not in
BxPC3.Neo cells. Further, we showed that compared to
the unconjugated NPs, TAB004 conjugated NPs had
significantly enhanced and prolonged cellular accumula-
tion in the BxPC3.MUC1 versus BxPC3.Neo cells confirm-
ing antigen specific targeted internalization (Fig. 5). This
enhanced cellular internalization and accumulation of
T-NPs over NPs is most likely due to the specific binding
of TAB004 to tumor form of MUC1 expressed on BxPC3.
MUC1 cells thus enabling the NPs to readily internalize
through a process of macropinocytosis [50]. Although
modest, PTX-loaded T-NPs showed significantly enhanced
cytotoxicity (Fig. 6) in an antigen specific manner. The
modest enhancement of cytotoxicity may be attributed to
the limited time (1.5 h) of exposure of cells to the drug.
Longer incubation with the nanoparticles caused degrad-
ation of the NPs, which then interfered with the OD values
in the survival assay. It is well established that the antitu-
mor effect of PTX results from its intracellular accumula-
tion over time [51]. In vivo in an immune compromised
mouse model, we observed specific localization and accu-
mulation of TAB004 only to the orthotropic BxPC3.MUC1
tumors generated in the pancreas (Fig. 7) but not in
MUC1-negative tumors or in normal epithelial organs
[34]. In a pilot in vivo experiment using immune com-
petent mice, we showed that compared to ICG-NPs,
TAB004 conjugated ICG-NPs accumulated in the KCM
tumor while unconjugated ICG-NPs failed to accumulate
in the tumor (Additional file 2: Figure S2). Thus, we
believe that the modest cytotoxic advantage observed in
vitro will be significantly enhanced in vivo. Future stud-
ies will evaluate the in vivo efficacy of various drug
loaded TAB004-NPs in several PDA models. Taken
together the data validates the tumor specificity of
TAB004 and that loaded NPs conjugated to TAB004
may be a promising nanocarrier for targeted therapy
and imaging of PDA.
Conclusion
Conjugation of NPs to TAB004 greatly enhanced the
internalization, retention, and targeting ability of NPs
in vitro and in vivo in orthotopic models of human and
mouse PDA. TAB004 conjugated PTX loaded NPs
showed modest but significant increase in cytotoxicity
against PDA cells in vitro. The anti-tumor efficacy of
chemotherapeutic drugs in vivo will need to be investi-
gated using this delivery platform.
Additional files
Additional file 1: Figure S1. Confirmation of TAB004 conjugation to
PLGA NPs with FACS. Blank NPs were treated with: (A) control (red), TAB004
(blue), anti-mouse IgG1 FITC (green), and both TAB004 and anti-mouse IgG1
FITC (orange/yellow); (B) control (red), NHS Ester linking reagent (blue), and NHS
Ester linking reagent,TAB004, and anti-mouse IgG1 FITC (green). (JPG 135 kb)
Additional file 2: Figure S2. In vivo imaging of ICG loaded NPs and
ICG loaded T-NPs orthotopically injected bioluminescent tumor bearing
mice (ICG - red/yellow, tumor – rainbow, n = 3): (A) ICG loaded NPs
injected into tumor bearing mouse; (B) ICG loaded T-NPs injected into
tumor bearing mouse; (C) ex vivo imaging of liver and tumor from (A)
and (B). (JPG 173 kb)
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